US 11,944,104 B2
Variant maltogenic alpha-amylase
Joke Anneleen Putseys, Echt (NL); Aloysius Wilhelmus Rudolphus Hubertus Teunissen, Echt (NL); René Marcel De Jong, Echt (NL); Jeroen Godefrooij, Echt (NL); and Helma Arina Stolze-Lagerweij, Echt (NL)
Assigned to DSM IP ASSETS B.V., Heerlen (NL)
Appl. No. 17/045,062
Filed by DSM IP ASSETS B.V., Heerlen (NL)
PCT Filed Apr. 4, 2019, PCT No. PCT/EP2019/058523
§ 371(c)(1), (2) Date Oct. 2, 2020,
PCT Pub. No. WO2019/193102, PCT Pub. Date Oct. 10, 2019.
Claims priority of application No. 18165871 (EP), filed on Apr. 5, 2018.
Prior Publication US 2021/0161158 A1, Jun. 3, 2021
Int. Cl. C12N 9/26 (2006.01); A21D 8/04 (2006.01)
CPC A21D 8/042 (2013.01) [C12N 9/2414 (2013.01); C12Y 302/01133 (2013.01)] 19 Claims
 
1. A variant polypeptide having maltogenic alpha-amylase activity wherein, the variant polypeptide comprises an amino acid sequence, which, when aligned with an amino acid sequence of SEQ ID NO: 1, comprises amino acid substitutions F188L, S200N, and D261G, and optionally a further amino acid substitution T288P, wherein the amino acid substitutions are determined with reference to SEQ ID NO: 1, and wherein the variant polypeptide has an amino acid sequence which has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or at least 99% identity to the amino acid sequence of SEQ ID NO: 1.